Compare GILD & BBVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GILD | BBVA |
|---|---|---|
| Founded | 1987 | 1857 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4B | 163.1B |
| IPO Year | 2003 | 2002 |
| Metric | GILD | BBVA |
|---|---|---|
| Price | $156.45 | $24.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 28 | 3 |
| Target Price | ★ $159.85 | $27.53 |
| AVG Volume (30 Days) | ★ 4.9M | 1.6M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | 2.09% | ★ 3.62% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.36 | $15.53 |
| Revenue Next Year | $6.88 | $6.60 |
| P/E Ratio | ★ N/A | $11.24 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $114.02 | $19.82 |
| 52 Week High | $160.51 | $29.64 |
| Indicator | GILD | BBVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 31.21 |
| Support Level | $142.91 | $24.90 |
| Resistance Level | $158.90 | $25.10 |
| Average True Range (ATR) | 3.75 | 0.39 |
| MACD | 0.55 | -0.10 |
| Stochastic Oscillator | 81.19 | 14.26 |
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Despite its Spanish origins, Banco Bilbao Vizcaya Argentaria generates only around one-fourth of its profits in Spain. We expect that on a normalized basis, BBVA's market-leading Mexican bank should contribute half of its earnings, while its Turkish operation should account for another 15%. The balance of BBVA's earnings comes from smaller operations in South America. BBVA is overwhelmingly a retail and commercial bank, with corporate and investment banking forming a minor part of the overall business. BBVA also offers insurance and investment products through its banking networks.